{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T01:47:55Z","timestamp":1781920075183,"version":"3.54.5"},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2020,10,31]],"date-time":"2020-10-31T00:00:00Z","timestamp":1604102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Toxic epidermal necrolysis (TEN) is a severe cutaneous reaction that can be life-threatening. In the United States, there are no established guidelines for the treatment of TEN. Supportive care including fluids and supportive therapies are the current recommendations. Research surrounding TEN involves mostly case studies or small, uncontrolled studies. Recent literature describes the use of tumor necrosis factor blockers in the treatment of TEN with positive results. These case reports describe decreased time to reepithelization, hospital length of stay, and minimal side effects. Conversely, we present three fatalities after the administration of etanercept.<\/jats:p>","DOI":"10.1093\/jbcr\/iraa194","type":"journal-article","created":{"date-parts":[[2020,10,31]],"date-time":"2020-10-31T10:51:01Z","timestamp":1604141461000},"page":"586-589","source":"Crossref","is-referenced-by-count":5,"title":["A Cautionary Tale of Etanercept Use in Patients With Toxic Epidermal Necrolysis"],"prefix":"10.1093","volume":"42","author":[{"given":"Janie","family":"Faris","sequence":"first","affiliation":[{"name":"Detroit Receiving Hospital, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Wilson","sequence":"additional","affiliation":[{"name":"Detroit Receiving Hospital, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather S","family":"Dolman","sequence":"additional","affiliation":[{"name":"Michael and Marian Ilitch Department of Surgery, Wayne State University School of Medicine, Detroit, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Isaacson","sequence":"additional","affiliation":[{"name":"Michael and Marian Ilitch Department of Surgery, Wayne State University School of Medicine, Detroit, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred E","family":"Baylor","sequence":"additional","affiliation":[{"name":"Wayne State University School of Medicine\/Detroit Medical Center Affiliated Hospitals, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James G","family":"Tyburski","sequence":"additional","affiliation":[{"name":"Detroit Receiving Hospital, Michigan"},{"name":"Wayne State University School of Medicine, Detroit, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T","family":"White","sequence":"additional","affiliation":[{"name":"Detroit Receiving Hospital, Michigan"},{"name":"Wayne State University School of Medicine, Detroit, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,10,31]]},"reference":[{"key":"2021050715270662300_CIT0001","first-page":"E15","article-title":"Tumor necrosis factor alpha inhibitors in the treatment of toxic epidermal necrolysis","volume":"101","author":"Woolridge","year":"2018","journal-title":"Cutis"},{"key":"2021050715270662300_CIT0002"},{"key":"2021050715270662300_CIT0003","volume-title":"Enbrel\u00ae (Etanercept) [package insert]","year":"2018"},{"key":"2021050715270662300_CIT0004","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jaad.2014.04.044","article-title":"Etanercept therapy for toxic epidermal necrolysis","volume":"71","author":"Paradisi","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"2021050715270662300_CIT0005","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.dsi.2012.06.005","article-title":"Use of etanercept to treat toxic epidermal necrolysis in a human immunodeficiency virus positive patient","volume":"31","author":"Lee","year":"2013","journal-title":"Dermatologica Sinica"},{"key":"2021050715270662300_CIT0006","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1111\/jdv.13330","article-title":"Successful use of etanercept in a case of toxic epidermal necrolysis induced by rituximab","volume":"30","author":"Didona","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2021050715270662300_CIT0007","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1345\/aph.1K001","article-title":"Etanercept for toxic epidermal necrolysis","volume":"41","author":"Famularo","year":"2007","journal-title":"Ann Pharmacother"},{"key":"2021050715270662300_CIT0008","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1346-8138.2009.00616.x","article-title":"Toxic epidermal necrolysis successfully treated with etanercept","volume":"36","author":"Gubinelli","year":"2009","journal-title":"J Dermatol"},{"key":"2021050715270662300_CIT0009","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/j.burns.2018.12.018","article-title":"Combination therapy: etanercept and intravenous immunoglobulin for the acute treatment of Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"45","author":"Pham","year":"2019","journal-title":"Burns"},{"key":"2021050715270662300_CIT0010","doi-asserted-by":"crossref","first-page":"e12832","DOI":"10.1111\/dth.12832","article-title":"Rapid remission of Stevens-Johnson syndrome by combination therapy using etanercept and intravenous immunoglobulin and a review of the literature","volume":"32","author":"Wang","year":"2019","journal-title":"Dermatol Ther"},{"key":"2021050715270662300_CIT0011","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jaip.2017.11.023","article-title":"SJS\/TEN 2017: building multidisciplinary networks to drive science and translation","volume":"6","author":"White","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2021050715270662300_CIT0012","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s12325-017-0530-y","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: a concise review with a comprehensive summary of therapeutic interventions emphasizing supportive measures","volume":"34","author":"Schneider","year":"2017","journal-title":"Adv Ther"}],"container-title":["Journal of Burn Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jbcr\/advance-article-pdf\/doi\/10.1093\/jbcr\/iraa194\/34675536\/iraa194.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jbcr\/article-pdf\/42\/3\/586\/37889210\/iraa194.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jbcr\/article-pdf\/42\/3\/586\/37889210\/iraa194.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T12:27:55Z","timestamp":1620476875000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbcr\/article\/42\/3\/586\/5945247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,31]]},"references-count":12,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,10,31]]},"published-print":{"date-parts":[[2021,5,7]]}},"URL":"https:\/\/doi.org\/10.1093\/jbcr\/iraa194","relation":{},"ISSN":["1559-047X","1559-0488"],"issn-type":[{"value":"1559-047X","type":"print"},{"value":"1559-0488","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,5,1]]},"published":{"date-parts":[[2020,10,31]]}}}